Curis (CRIS) Competitors $3.08 +0.01 (+0.33%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CRIS vs. RGLS, AGEN, FBIO, SABS, BOLT, MTEM, AMGN, VRTX, GILD, and REGNShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Regulus Therapeutics (RGLS), Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry. Curis vs. Regulus Therapeutics Agenus Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Regulus Therapeutics (NASDAQ:RGLS) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings. Does the media refer more to RGLS or CRIS? In the previous week, Regulus Therapeutics had 3 more articles in the media than Curis. MarketBeat recorded 3 mentions for Regulus Therapeutics and 0 mentions for Curis. Regulus Therapeutics' average media sentiment score of 0.96 beat Curis' score of 0.00 indicating that Regulus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Regulus Therapeutics Positive Curis Neutral Do insiders and institutionals hold more shares of RGLS or CRIS? 92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by insiders. Comparatively, 5.7% of Curis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, RGLS or CRIS? Regulus Therapeutics has higher earnings, but lower revenue than Curis. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegulus TherapeuticsN/AN/A-$30.04M-$1.07-1.49Curis$10.26M2.54-$47.41M-$7.81-0.39 Is RGLS or CRIS more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Curis' net margin of -443.35%. Regulus Therapeutics' return on equity of -53.07% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Regulus TherapeuticsN/A -53.07% -48.58% Curis -443.35%-923.37%-78.35% Which has more risk & volatility, RGLS or CRIS? Regulus Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.34, indicating that its stock price is 234% more volatile than the S&P 500. Do analysts rate RGLS or CRIS? Regulus Therapeutics presently has a consensus target price of $10.80, indicating a potential upside of 579.25%. Curis has a consensus target price of $23.00, indicating a potential upside of 646.75%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Regulus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regulus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Curis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor RGLS or CRIS? Curis received 203 more outperform votes than Regulus Therapeutics when rated by MarketBeat users. Likewise, 67.81% of users gave Curis an outperform vote while only 63.80% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformRegulus TherapeuticsOutperform Votes49063.80% Underperform Votes27836.20% CurisOutperform Votes69367.81% Underperform Votes32932.19% SummaryRegulus Therapeutics beats Curis on 9 of the 17 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.08M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.3946.7390.0517.18Price / Sales2.54415.011,117.14116.99Price / CashN/A182.1043.0437.86Price / Book0.923.894.784.78Net Income-$47.41M-$42.21M$120.31M$225.60M7 Day Performance-13.73%-2.15%-1.92%-1.23%1 Month Performance-24.88%4.20%11.51%3.36%1 Year Performance-75.73%18.39%30.61%16.60% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.7846 of 5 stars$3.08+0.3%$23.00+646.8%-74.6%$26.08M$10.26M-0.3949High Trading VolumeRGLSRegulus Therapeutics2.7405 of 5 stars$1.67+5.4%$10.80+548.6%+20.5%$109.06MN/A-1.4830News CoveragePositive NewsAGENAgenus3.6855 of 5 stars$2.88-5.6%$10.00+247.2%-81.2%$67.56M$160.43M-0.27389FBIOFortress Biotech3.1454 of 5 stars$1.89-2.8%$13.67+625.0%-27.1%$52.04M$62.50M-0.63186SABSSAB Biotherapeutics2.4276 of 5 stars$4.01-1.7%$12.40+209.2%+520.0%$37.01M$2.24M0.00140Gap UpBOLTBolt Biotherapeutics2.4704 of 5 stars$0.52-0.9%$3.50+569.2%-50.5%$20.02M$7.88M-0.31100MTEMMolecular Templates3.1833 of 5 stars$0.39-2.5%N/A-95.7%$2.57M$57.31M-0.1562News CoverageGap DownAMGNAmgen4.4684 of 5 stars$269.31-0.5%$319.68+18.7%-4.3%$144.76B$32.53B34.8626,700Analyst DowngradeGap UpVRTXVertex Pharmaceuticals4.7433 of 5 stars$467.62+0.8%$505.73+8.1%-0.7%$120.43B$9.87B-233.035,400Analyst ForecastAnalyst RevisionNews CoverageGILDGilead Sciences4.4898 of 5 stars$92.72+0.9%$96.43+4.0%+17.8%$115.55B$27.12B1,020.6718,000Insider TradeREGNRegeneron Pharmaceuticals4.6599 of 5 stars$733.09+0.2%$1,099.90+50.0%-16.6%$80.56B$13.12B18.1013,450Analyst Forecast Related Companies and Tools Related Companies Regulus Therapeutics Competitors Agenus Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Vertex Pharmaceuticals Competitors Gilead Sciences Competitors Regeneron Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRIS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
